SOONSIXThe short version
Sonova Holding AG
Sonova is the world's largest hearing-aid maker — Phonak, Unitron, Advanced Bionics and a large retail network — a Swiss blue-chip whose sales, margins and share price have all stepped down since a 2021 peak.
Over the past six months the shares fell from $276 in January to a $210 low in late March, then recovered to $257 — still about half the late-2021 peak.
$257
Share price
$15.3bn
Market cap
$4.51bn
FY2026 sales
17.4%
Founder ownership
SwipeScroll▾
The statements
Flat sales, a four-point margin step-down, cash intact
FY2022 → FY2026as reported · $
Revenue$4.5B+3%
Operating margin18.7%+0.8pp
Net income$550M−11%
EPS$9.03−12%
Free cash flow$744M+0%
Open the full statements →Fiscal year ends 31 March; FY2026 figures are continuing operations.
- Sales went sideways. After a post-pandemic surge, group revenue held near $4.5bn for four years; continuing-operations sales were $4,509.5m in FY2026 — down 0.2% in francs, up 5.9% in local currency.
- Margins stepped down, then steadied. Reported EBIT margin fell from 22.6% in FY2022 to 18.7% in FY2026; the normalized EBITA margin troughed at 20.6% in FY2024 and has recovered to 22.5%.
- Cash held up. Free cash flow was $592.4m in FY2026 and net debt fell to $1.24bn, about 1.2x normalized operating profit; the dividend rose to a record $5.88.
Consumer Hearing (Sennheiser) was reclassified to discontinued operations in FY2026.
The growth engine
A widening Wholesale lead, won on a shrinking R&D budget
Latest-year hearing-aid growth, local currency
A ~7pp lead delivered as R&D intensity fell from 6.8% to 6.0% of sales.
- The finding. Sonova's growth engine is an accelerating, high-margin Wholesale franchise (+9.5% local, segment margin up to 23.7%) but its ~7pp lead over Demant (+2% organic) was delivered on falling R&D intensity (6.8% -> 6.0% of sales), so the Sphere lead is a timing edge to be re-won every two to three years rather than a structural, spend-driven moat.
- The counter. Rivals already ship on-device AI — Oticon Intent arrived in early 2024, before Sphere — and the falling R&D intensity may be operating leverage on a front-loaded six-year DEEPSONIC build, extended by Infinio Ultra in October 2025.
- Why it matters. The exit multiple, not EPS, drives the two-year return: Wholesale growth converging toward the 4–6% market points to a bear ~16x case worth about a 15% loss, while a sustained premium supports a re-rating.
What backs the equity
A questionable capital record, sitting over no asset floor
FY2026 shareholders' equity, by asset backing
Goodwill$2,856.6M87%
Acquisition intangibles$279.9M8%
Capitalised development$101.2M3%
Software & other$40M1%
Tangible net assets$18.5M1%
Equity of $3,296m at 31 March 2026; goodwill alone is ~87%.
- The finding. Sonova spent ~$1.56bn near the cycle top — $1.21bn of buybacks at ~$343 and $352m on Sennheiser now exiting at a $133m loss — on top of an equity base that is ~100% intangible (tangible book $18.5m, goodwill ~87% of the $3,297m equity), so a questionable capital-allocation record sits over no asset floor.
- The counter. Net debt fell from $1,632.0m to $1,243.5m, ROCE is 19.0%, buybacks shrank the share count about 7.4%, and the goodwill clears its impairment tests with a pre-tax WACC raised to 10.9% and a 1pp cushion to spare.
- Where safety sits. With tangible book at $18.5m there is no book-value floor; downside protection rests on net debt near 1.2x normalized EBITA and ~95% cash conversion, not on assets.
The demand backdrop
A low-penetration market that ages in the company's favour
~430M
People with moderate-or-worse hearing loss
4–6%
Structural hearing-aid market growth per year
32%
Developed-market adoptionjust 2% in China & India
- Demand is durable. About 1.5 billion people live with some hearing loss and roughly 430 million have moderate-or-worse loss; most go untreated, and the treated population grows as societies age.
- Penetration is the runway. Developed markets fit hearing aids to about a third of those who need them; in China and India it is nearer 2%, leaving a long adoption curve ahead.
Moat and OTC threat
A standing margin lead over Demant, and the OTC question
Normalized operating margin: Sonova vs Demant
| Year | Sonova EBITA% | Demant EBIT% |
|---|---|---|
| FY2022 | 24.7% | 20.5% |
| FY2023 | 22.1% | 16.3% |
| FY2024 | 20.6% | 20.9% |
| FY2025 | 21.6% | 19.6% |
| FY2026 | 22.5% | 17.2% |
Sonova on normalized EBITA, Demant on reported EBIT; peer years lag Sonova's by one.
- The margin gap persists. Sonova's normalized EBITA margin has sat above Demant's operating margin in four of the last five years, widening again to 22.5% versus 17.2% most recently.
- The OTC threat is bounded, so far. U.S. regulators cleared AirPods-as-hearing-aid software in September 2024, but OTC targets milder loss than Sonova's prescription base; the effect has been additive, not substitutive.
- Share gains held through the downturn. Sonova kept taking prescription share while the multiple de-rated — evidence its franchise did not break.
Segment economics
One big prescription franchise, one small implant business
FY2026 external sales by channel
Wholesale (devices)$2,328.4M52%
Retail (stores)$1,865.8M41%
Cochlear Implants$315.3M7%
Hearing Instruments is 93% of sales and about 98% of segment profit.
- Wholesale plus retail is the engine. The Hearing Instruments segment — prescription devices sold wholesale and through owned stores — is $4,194.2m of sales and nearly all the profit.
- Cochlear Implants is small and shrinking. Implant sales fell to $315.3m in FY2026, down 11.1% in local currency; it is 7% of sales and about 2% of profit.
- Little of the top line is bought. Growth is overwhelmingly organic rather than acquired — the reassurance for an owner asking how much revenue is earned versus purchased.
The currency wedge
Real growth in local currency, masked by a strong franc
FY2026 growth: local currency vs reported francs
The franc turned +5.9% local sales into roughly flat reported sales.
- The franc hides the operating result. Local-currency sales rose 5.9% and normalized EBITA 17.3%, yet in francs those became -0.2% and +3.7%; currency cut normalized EBITA by about $133m.
- A franc-paying owner banks the reported line. On reported figures, EPS including discontinued operations fell about 20% and ROCE eased from 24.1% to 19.0% — the translation drag is real to a Swiss shareholder.
- What decides it. Whether the franc drag persists or reverses is largely exogenous; it is worth watching rather than forecasting.
Owners and stewards
Founders hold the largest block; the stewards bought high
Largest shareholders
| Holder | Stake |
|---|---|
| Diethelm family (founder) | 11.26% |
| Rihs family (founder) | 6.18% |
| UBS Fund Management | 5.48% |
| BlackRock | 5.10% |
| Board + management | 0.10% |
Founding families together hold ~17.4%; the board and management own ~0.10%.
- Skin in the game is founder, not manager. The Diethelm and Rihs families hold about 17.4% — worth roughly $2.7bn — while the board and executives own about 0.10% combined.
- Pay is modest and gated. The CEO's total was $3.26m and the say-on-pay vote passed with about 90% support; compensation is tied to ROCE.
- The buybacks were mistimed. Sonova repurchased stock at ~$364 and ~$318 in FY2022-23, well above today's $257; none have run since FY2024.
Capital returns
A rising dividend, but buybacks stopped after the cycle top
Capital returned to shareholders ($m)
$1.21bn of buybacks in FY2022-23; none since.
- The dividend never blinked. Distributions rose through the entire de-rating to a record $5.88 per share, one cut aside across five years.
- Buybacks lapsed at the wrong time. After spending $1.21bn near the top, the programme went quiet; restarting near $257 would read as a stewardship upgrade.
- The forward view is modest growth. Consensus sees sales reaching about $4.96bn and EPS near $13.97 by FY2028 — roughly 8% annual EPS growth.
What the price implies
The fall was mostly multiple, not earnings
From the 2021 peak to today
| Point | Price | P/E |
|---|---|---|
| 31 Mar 2022 close | $419.10 | 36.7x |
| Late-2021 peak (market data) | ~$434.60 | 38.0x |
| 23 Jul 2026 | $256.60 | 20.1x |
Normalized continuing EPS was near flat in local terms; the multiple roughly halved.
- Multiple did the work. The ~46–48% de-rating came almost entirely from a lower P/E — normalized continuing EPS is essentially unchanged over the period.
- The price already assumes little. At $257 the shares imply only about 4% long-run growth, giving no credit for share gains or buybacks.
- The debate is the exit multiple. Whether about 20x is a cyclical trough or the new normal for a stepped-down franchise is what the report weighs.
Valuation
Priced like a slow compounder, not a fallen growth name
20.7x
Forward P/E (FY2027E)
16.6x
EV / normalized EBITA
4.2%
Operating free-cash-flow yield
2.2%
Dividend yield
- Cheaper than its own history, dearer than Demant. Roughly 20x forward earnings sits well below the ~38x 2021 peak but above a re-rated-down Demant.
- Yield support builds as debt falls. The 4.2% operating free-cash-flow yield rises toward 5% on FY2027 estimates as net debt keeps shrinking.
EV of about $16.9bn over $1,014.5m normalized EBITA.
Scenarios
Two years out, the exit multiple decides the outcome
FY2028 price scenarios
Bear (16x)
$206
Base (20x)
$289
Bull (24x)
$368
Total returns of about -15%, +18% and +48% including dividends.
- The spread is wide and multiple-driven. A ~50% swing in the exit multiple moves the two-year return far more than the ~19% swing in EPS across the cases.
- Downside is buffered, not floored. The bear case is about a 15% loss, cushioned by low leverage and cash generation rather than by any asset value.
- The bull needs the premium to hold. A re-rating toward 24x on sustained share gains delivers roughly a 48% total return.
What to watch
A cash-rich leader at half its old multiple: durable franchise overpunished, or a permanent step-down.
- 01Wholesale local-currency growth sustained below ~6% would signal convergence toward the 4–6% market and a fading lead.
- 02Normalized EBITA margin above ~24% marks the recovery complete; below ~21% reads as structural.
- 03US growth and pricing: deceleration with explicit managed-care or ASP-pressure language is the live near-term risk.
- 04Capital allocation: buybacks restarting near $257 with a clean Sennheiser exit would be a stewardship upgrade.
This distills a guided study built chapter by chapter — from the statements through the moat, the capital record, and what the price implies.
Compiled from the full report · 2026-07-24 · For information, not investment advice.